John Overdeck’s InMed Pharmaceuticals INM Stock Holding History

John Overdeck’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-79	Closed	-$37K	–	2714
2022 Q1	$37K	Sell	79 -184	-70%	-$96.6K	﹤0.01%	2506
2021 Q4	$172K	Buy	+263	New	+$204K	﹤0.01%	3963

Other funds holding INM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

John Overdeck's INM Position: Q2 2022 in Review

John Overdeck sold out of InMed Pharmaceuticals (INM) in Q2 2022, closing a stake of 79 shares — an estimated $37K sold.

John Overdeck first reported a position in INM in Q4 2021 and held it in 2 quarters. The position peaked at $172K in Q4 2021. 11 funds tracked by Wall St. Rank hold INM as of Q2 2022.

John Overdeck reported no remaining InMed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
John Overdeck sold 79 InMed Pharmaceuticals shares in Q2 2022, an estimated $37K.
John Overdeck first reported a position in InMed Pharmaceuticals in Q4 2021 and held it in 2 quarters.
John Overdeck's InMed Pharmaceuticals position peaked at $172K in Q4 2021.
11 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2022.

Based on Two Sigma Investments's 13F filing for Q2 2022, filed 15 Aug 2022.